Search our Database of Scientific Publications and Authors

I’m looking for a

    8657 results match your criteria Psoriatic Arthritis

    1 OF 174

    Effect of Biologics on Fatigue in Psoriatic Arthritis: A Systematic Literature Review with Meta-analysis.
    Joint Bone Spine 2018 Feb 13. Epub 2018 Feb 13.
    Rheumatology Department, Pitie-Salpétrière Hospital, AP-HP, 75013, Paris, France.
    Objectives: Fatigue is a significant issue in psoriatic arthritis. The objective was to assess the effect of biological disease modifying antirheumatic drugs and apremilast on fatigue in psoriatic arthritis randomised controlled trials and to compare this effect with the effect in the same trials, on pain, through a systematic literature review and meta-analysis.

    Methods: A systematic literature review was performed up to January 2017 in PubMed, Embase and Cochrane databases. Read More

    Early Psoriatic Arthritis Versus Early Seronegative Rheumatoid Arthritis: Role of Dermoscopy Combined with Ultrasonography for Differential Diagnosis.
    J Rheumatol 2018 Feb 15. Epub 2018 Feb 15.
    From the Department of Medical and Biological Sciences, Rheumatology Clinic, and the Department of Experimental and Clinical Medicine, Institute of Dermatology, University of Udine, Udine, Italy. A. Zabotti, MD, Department of Medical and Biological Sciences, Rheumatology Clinic, University of Udine; E. Errichetti, MD, Department of Experimental and Clinical Medicine, Institute of Dermatology, University of Udine; F. Zuliani, MD, Department of Medical and Biological Sciences, Rheumatology Clinic, University of Udine; L. Quartuccio, MD, PhD, Department of Medical and Biological Sciences, Rheumatology Clinic, University of Udine; S. Sacco, MD, Department of Medical and Biological Sciences, Rheumatology Clinic, University of Udine; G. Stinco, MD, Department of Experimental and Clinical Medicine, Institute of Dermatology, University of Udine; S. De Vita, MD, Department of Medical and Biological Sciences, Rheumatology Clinic, University of Udine. Alen Zabotti and Enzo Errichetti contributed equally to this work. Address correspondence to Dr. S. De Vita, Rheumatology Clinic, "Santa Maria della Misericordia" University Hospital, Piazzale Santa Maria della Misericordia, 15, 33100-Udine, Italy. E-mail: Accepted for publication November 21, 2017.
    Objective: Exclusion of psoriatic skin/nail lesions is important in differentiating early seronegative rheumatoid arthritis (ERA) from early polyarticular psoriatic arthritis (EPsA) and such manifestations may go unnoticed in atypical or minimally expressed cases. The aim of this study is to assess the usefulness of integrated rheumatological-dermatological evaluation in highlighting dermatological lesions missed on rheumatological examination and to investigate the role of ultrasonography (US) and dermoscopy in improving the recognition of subclinical psoriatic findings.

    Methods: Patients with a new diagnosis of seropositive or seronegative ERA and EPsA with prevalent hands involvement were recruited. Read More

    Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis.
    J Rheumatol 2018 Feb 15. Epub 2018 Feb 15.
    From The University of Texas Medical Branch, Galveston, Texas; Real Life Sciences Inc., New York; CreakyJoints, Global Healthy Living Foundation, Upper Nyack, New York; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; Kinapse Ltd., London, UK. Sponsored by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. The design and conduct of this research was a collaborative effort between Kinapse and Novartis, and financial support for this research was provided by Novartis. Novartis participated in the interpretation of data, and review and approval of the manuscript. Support for third-party writing assistance for this manuscript, furnished by Eric Deutsch, PhD, of Health Interactions Inc., was provided by Novartis Pharmaceuticals Corporation. P. Sunkureddi, MD, The University of Texas Medical Branch; S. Doogan, BA, Real Life Sciences Inc.; J. Heid, BA, Kinapse Ltd.; S. Benosman, DVM, PhD, Kinapse Ltd.; A. Ogdie, MD, MSCE, Perelman School of Medicine at the University of Pennsylvania; L. Martin, RN, CreakyJoints, Global Healthy Living Foundation; J.B. Palmer, PharmD, Novartis Pharmaceuticals Corporation. Address correspondence to Dr. P. Sunkureddi, 2060 Space Park Drive, Suite 208, Nassau Bay, Texas 77058, USA. E-mail: Full Release Article. For details see Reprints and Permissions at Accepted for publication November 7, 2017.
    Objective: To evaluate the types of experiences and treatment access challenges of patients with psoriatic arthritis (PsA) using self-reported online narratives.

    Methods: English-language patient narratives reported between January 2010 and May 2016 were collected from 31 online sources (general health social networking sites, disease-focused patient forums, treatment reviews, general health forums, mainstream social media sites) for analysis of functional impairment and 40 online sources for assessment of barriers to treatment. Using natural language processing and manual curation, patient-reported experiences were categorized into 6 high-level concepts of functional impairment [social, physical, emotional, cognitive, role activity (SPEC-R), and general] and 6 categories to determine barriers to treatment access (coverage ineligibility, out-of-pocket cost, issues with assistance programs, clinical ineligibility, formulary placement/sequence, doctor guidance). Read More

    Pain threshold and temporomandibular function in systemic sclerosis: comparison with psoriatic arthritis.
    Clin Rheumatol 2018 Feb 14. Epub 2018 Feb 14.
    Division of Rheumatology, Department of Clinical and Experimental Medicine, Policlinico Universitario "G. Martino", University of Messina, Via Consolare Valeria, 98125, Messina, Italy.
    The aim of the study was to evaluate whether a reduced pain threshold is associated with increased temporomandibular dysfunction in systemic sclerosis (SSc) compared to psoriatic arthritis (PsA) and healthy controls. Ninety subjects participated in the study (30 SSc, 30 PsA, and 30 healthy controls). The Helkimo index was used to evaluate temporomandibular dysfunction. Read More

    Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study).
    J Eur Acad Dermatol Venereol 2018 Feb 14. Epub 2018 Feb 14.
    Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany.
    Background: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy and a favorable safety profile in the treatment of moderate to severe psoriasis and psoriatic arthritis.

    Objective: To assess the efficacy and safety of secukinumab through 5 years of treatment in moderate to severe psoriasis.

    Methods: In the core SCULPTURE study, Psoriasis Area and Severity Index (PASI) 75 responders at Week 12 continued receiving subcutaneous secukinumab until Year 1. Read More

    Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review.
    Pharmacoeconomics 2018 Feb 13. Epub 2018 Feb 13.
    Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy.
    Background: Psoriatic arthritis is a long-term inflammatory arthropathy occurring in a subgroup of patients with psoriasis. In addition to irreversible bone erosions, joint destruction, and skin manifestations, psoriatic arthritis is associated with numerous comorbid conditions. Over the last 5 years, new treatments emerged; the analysis and comparisons of their additional costs and the added benefits have become increasingly important to optimize the limited resources available. Read More

    A review of ustekinumab in the treatment of psoriatic arthritis.
    Immunotherapy 2018 Feb 14. Epub 2018 Feb 14.
    Faculty of Medicine, Memorial University of Newfoundland, St John's, Newfoundland & Labrador, Canada.
    Psoriatic arthritis is an inflammatory arthritis associated with psoriasis. The IL-23/IL-17 axis is an important pathway in the development of psoriatic disease. Ustekinumab is a fully human monoclonal IgG1 antibody that binds to the p40 subunit of IL-12 and IL-23, which, in turn, inhibits downstream signaling pathways. Read More

    "STATus of STAT3 in Psoriatic Arthritis."
    Arthritis Rheumatol 2018 Feb 13. Epub 2018 Feb 13.
    Division of Clinical Immunology and Rheumatology, Dept. of Medicine, Shelby Interdisciplinary Biomed Research Bldg. Room SHEL, 307 1825 University Blvd, Birmingham, AL, 35294-2182.
    Joint disease and enthesopathy are seen in about one-third of patients with psoriasis and are usually preceded by the cutaneous manifestations of psoriasis. The relationships between the pathogenesis of psoriatic skin disease and the pathogenesis of psoriatic arthritis have not been defined, however, and the central question as to whether psoriatic skin disease initiates development of joint disease remains unresolved. This article is protected by copyright. Read More

    Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis.
    Arthritis Rheumatol 2018 Feb 13. Epub 2018 Feb 13.
    Department of Pathology, NYU School of Medicine, New York, NY, 10016.
    Objective: To introduce a novel pre-clinical animal model of psoriatic arthritis, R26STAT3CCD4Cre mice, and investigate the role of Th17 cytokines in the disease pathogenesis.

    Methods: We characterized a novel murine model of Th17-driven cutaneous and synovio-entheseal disease directed by T cell-specific expression of a hyperactive STAT3 allele. By crossing R26STAT3CCD4Cre mice onto an IL-22 knockout background or treating them with a neutralizing antibody against IL-17, we interrogated how these Th17 cytokines contribute to disease pathogenesis. Read More

    Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine.
    BMJ Open 2018 02 8;8(2):e018166. Epub 2018 Feb 8.
    Focused Research Unit for Molecular Diagnostic and Clinical Research, IRS-Center Sonderjylland, Hospital of Southern Jutland, Aabenraa, Denmark.
    Introduction: Chronic inflammatory diseases (CIDs) are frequently treated with biological medications, specifically tumour necrosis factor inhibitors (TNFi)). These medications inhibit the pro-inflammatory molecule TNF alpha, which has been strongly implicated in the aetiology of these diseases. Up to one-third of patients do not, however, respond to biologics, and lifestyle factors are assumed to affect treatment outcomes. Read More

    [What's new in internal medecine?]
    Ann Dermatol Venereol 2016 Dec;143 Suppl 3:S23-S28
    Service de dermatologie, hôpital Saint-Louis, INSERM U976, université Paris-Diderot-Paris VII, Sorbonne-Paris-Cité, Paris, France. Electronic address:
    Answering the question « what's new in internal medecine in 2016? » is very challenging. We used 3 methods of article selection to reduce the selection bias: 3 authors, a systematic review of the articles discussed in the weekly bibliographic meeting of our unit (Dermatology department, Saint-Louis Hospital, Paris, France) and a selection of the best articles by several internal medecine practitioners in Paris. Eleven « hot topics » were analyzed: i/lowering cholesterol level but not blood blessure has a significant impact on cardiovascular morbi-mortality in cardiovascular intermediate risk patients; ii/the « treat to treat target » is efficient in psoriatic arthritis; iii/ a genotype/ phenotype correlation favors the separation of ileal Crohn's disease, colonic Crohn's disease and ulcerative colitis; iv/ tocilizumab treatment (anti-IL-6 monoclonal antibody ) is very efficient in giant cell arteritis and slightly efficient in systemic sclerosis; v/ combination therapy using methotrexate plus steroids compared with steroids alone becomes the « gold standard » treatment for juvenile dermatomyositis; vi/ dupilumab treatment (antibody blocking IL-4 and IL-13 receptors) is not only efficient in atopic dermatitis but also in asthma; vii/ think of eosinophilic oesophagitis in a patient with atopic dermatitis and dypshagia or food impaction; viii/ genetic A2 protein dysfunction induces NF-kB hyperactivation and an autoinflammatory disorder with features similar to Behcet's disease; ix/ no new biotherapies have shown high efficacy in systemic lupus erythematosus; x/ nanoparticles loaded with autoantigens induce Tregs and Bregs and may be a promising therapeutic option to treat auto-immune disease in the future; xi/ ipilimumab treatment (anti-CTLA4 antibody, immune checkpoint inhibitor) may induce complete remission in acute myeloid leukemia patients relapsing after haematological stem cell transplantation. Read More

    Real-world burden of comorbidities in US patients with psoriatic arthritis.
    RMD Open 2017 28;3(2):e000588. Epub 2017 Dec 28.
    Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA.
    Objectives: We assessed comorbidities associated with psoriatic arthritis in a broad cohort of US-insured adult patients using the Truven Health Analytics MarketScan Database.

    Methods: Prevalence and incidence rates were assessed for 28 comorbid conditions among adult patients in the MarketScan database with a diagnosis of psoriatic arthritis and having two or more health claims for psoriatic arthritis between 1 July 2008 and 31 July 2015. Findings were compared with those of a similar, previously published analysis of patients with psoriasis. Read More

    RNA-Seq Analysis of IL-1B and IL-36 Responses in Epidermal Keratinocytes Identifies a Shared MyD88-Dependent Gene Signature.
    Front Immunol 2018 29;9:80. Epub 2018 Jan 29.
    Department of Dermatology, University of Michigan, Ann Arbor, MI, United States.
    IL-36 cytokines have recently emerged as mediators of inflammation in autoimmune conditions including psoriasis vulgaris (PsV) and generalized pustular psoriasis (GPP). This study used RNA-seq to profile the transcriptome of primary epidermal keratinocytes (KCs) treated with IL-1B, IL-36A, IL-36B, or IL-36G. We identified some early IL-1B-specific responses (8 h posttreatment), but nearly all late IL-1B responses were replicated by IL-36 cytokines (24 h posttreatment). Read More

    The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life (HRQoL) in patients with psoriasis: Analysis from the nationwide epidemiologic study for psoriasis in Korea (EPI-PSODE study).
    J Eur Acad Dermatol Venereol 2018 Feb 11. Epub 2018 Feb 11.
    Department of Dermatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
    Background: Psychological aspect and quality of life should be considered in treating patients with psoriasis.

    Objective: We sought to ascertain which clinical characteristics including presence of exposed lesions are associated with impairment of health-related quality of life (HRQoL) in patients with psoriasis.

    Methods: The EPI-PSODE study was a nationwide, multicenter, cross-sectional study conducted in Korea that included 1,260 adult patients with psoriasis. Read More

    Psoriatic arthritis screening by the dermatologist: development and first validation of the "PURE-4 scale".
    J Eur Acad Dermatol Venereol 2018 Feb 11. Epub 2018 Feb 11.
    Department of Rheumatology, Henri Mondor Hospital, APHP, and Université Paris Est Créteil, EA, 7379 - EpidermE,, F-94010, Créteil, France.
    Background: Dermatologists are recommended to ask psoriasis patients about musculoskeletal complaints to allow early detection and treatment of psoriatic arthritis (PsA). Screening tools have been developed to help identifying patients warranting further rheumatologic assessment, but evidence suggests room for improvement in their diagnostic value and ease of use for outpatient practice.

    Objective: To develop and internally validate a brief tool for dermatologists to screen patients to refer to a rheumatologist for PsA diagnosis. Read More

    Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases.
    Biologics 2018 31;12:37-41. Epub 2018 Jan 31.
    Immunology and Allergology Laboratory Unit, USL-Toscana Centro, Hospital S. Giovanni di Dio, Florence, Italy.
    Introduction: The aim of this study was to investigate the correlation between human leukocyte antigen (HLA) haplotypes and the development of antidrug antibodies (ADAs) in a cohort of patients with rheumatic diseases.

    Patients And Methods: We evaluated the presence of ADAs in 248 patients with inflammatory rheumatic diseases after 6 months of treatment with anti-TNF drugs: 26 patients were treated with infliximab (IFX; three with rheumatoid arthritis [RA], 13 with ankylosing spondylitis [AS], 10 with psoriatic arthritis [PsA]); 83 treated with adalimumab (ADA; 24 with RA, 36 with AS, 23 with PsA); 88 treated with etanercept (ETA; 35 with RA, 27 with AS, 26 with PsA); 32 treated with certolizumab (CERT; 25 with RA, two with AS, five with PsA); and 19 treated with golimumab (GOL; three with RA, seven with AS, nine with PsA). Serum drug and ADA levels were determined using Lisa-Tracker Duo, the ADA-positive samples underwent an inhibition test, and the true-positive samples underwent genetic HLA typing. Read More

    Enthesitis: A hallmark of psoriatic arthritis.
    Semin Arthritis Rheum 2018 Jan 6. Epub 2018 Jan 6.
    Intermountain Healthcare, Salt Lake City, UT.
    Objective: To describe the growing importance of enthesitis in patients with psoriatic arthritis (PsA) and discuss the advantages and disadvantages of clinical and imaging methods currently used to assess enthesitis.

    Methods: PubMed literature searches were conducted using the terms psoriatic arthritis, entheses, enthesitis, pathology, imaging, ultrasound, magnetic resonance imaging, clinical, and indices. Articles were deemed relevant if they provided insight into the pathology, monitoring, and/or diagnosis of enthesitis in PsA, or if they discussed clinical or imaging indices used to assess enthesitis. Read More

    Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints.
    Int J Mol Sci 2018 Feb 9;19(2). Epub 2018 Feb 9.
    Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute and Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.
    Psoriasis is a chronic systemic inflammatory disease causing erythematosus and scaly skin plaques; up to 30% of patients with psoriasis develop Psoriatic Arthritis (PsA), which is characterised by inflammation and progressive damage of the peripheral joints and/or the spine and/or the entheses. The pathogenic mechanisms driving the skin disorder in psoriasis and the joint disease in PsA are sustained by the activation of inflammatory pathways that can be overlapping, but also, at least partially, distinct. Cytokines members of the IL-23/IL-17 family, critical in the development of autoimmunity, are abundantly expressed within the cutaneous lesions but also seem to be involved in chronic inflammation and damage of the synovium though, as it will be here discussed, not in all patients. Read More

    Autoinflammatory keratinization diseases: An emerging concept encompassing various inflammatory keratinization disorders of the skin.
    J Dermatol Sci 2018 Feb 1. Epub 2018 Feb 1.
    Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan.
    Classifying inflammatory skin diseases is challenging, especially for the expanding group of disorders triggered by genetic factors resulting in hyperactivated innate immunity that result in overlapping patterns of dermal and epidermal inflammation with hyperkeratosis. For such conditions, the umbrella term "autoinflammatory keratinization diseases" (AIKD) has been proposed. AIKD encompasses diseases with mixed pathomechanisms of autoinflammation and autoimmunity, and includes IL-36 receptor antagonist (IL-36Ra)-related pustulosis, CARD14-mediated pustular psoriasis, pityriasis rubra pilaris (PRP) type V, and familial keratosis lichenoides chronica (KLC). Read More

    Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study.
    J Rheumatol 2018 Feb 1. Epub 2018 Feb 1.
    From the Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto; Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; Division of Dermatology, University of Toronto, Toronto Western Hospital, Toronto; Western University, London, Ontario; University of British Columbia, Vancouver, British Columbia; Memorial University of Newfoundland, St. John's, Newfoundland; University of Manitoba; Winnipeg Clinic, Winnipeg, Manitoba, Canada; University of Michigan Medical School, Ann Arbor, Michigan; Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA; Rheumatology Unit, Carmel Medical Center, Haifa, Israel. L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto; P. Harvey, BMBS, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto; V. Chandran, MD, DM, PhD, Department of Medicine, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; C.F. Rosen, MD, FRCPC, Department of Medicine, University of Toronto, and Division of Dermatology, University of Toronto, Toronto Western Hospital; J. Dutz, MD, FRCPC, University of British Columbia; J.T. Elder, MD, PhD, University of Michigan Medical School; P. Rahman, MD, MSc, FRCPC, Memorial University of Newfoundland; C.T. Ritchlin, MD, MPH, Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center; S. Rohekar, MD, FRCPC, Western University; R. Hayday, MD, FRCPC, University of Manitoba; S. Barac, MD, FRCPC, Winnipeg Clinic; J. Feld, MD, Rheumatology Unit, Carmel Medical Center; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center; D.D. Gladman, MD, FRCPC, Department of Medicine, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital. Address correspondence to Dr. L. Eder, Women's College Research Institute, Women's College Hospital, 76 Grenville St., Toronto, Ontario M5S 1B2, Canada. E-mail: Accepted for publication October 11, 2017.
    Objective: We aimed to estimate the proportion of underdiagnosis and undertreatment of cardiovascular risk factors (CVRF) in an international multicenter cohort of patients with psoriasis and psoriatic arthritis (PsA).

    Methods: A cross-sectional analysis was conducted of patients with psoriatic disease from the International Psoriasis and Arthritis Research Team cohort. The presence of modifiable CVRF [diabetes, hypertension (HTN), dyslipidemia, smoking, elevated body mass index, and central obesity] and the use of appropriate therapies for HTN and dyslipidemia were determined. Read More

    The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.
    J Rheumatol 2018 Feb;45(2):195-201
    From the Dipartimento di Medicina e Scienze della Salute "Vincenzo Tiberio," Università degli Studi del Molise, Campobasso; Day Hospital of Rheumatology, Azienda Sistema Socio Sanitario (ASST) Centro Specialistico Ortopedico Traumatologico G. Pini-Centro Specialistico Traumatologico-Ortopedico (CTO), Milan; Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Matera; La Struttura Semplice Dipartimentale (SSD) di Medicina e Reumatologia, Istituto Ortopedico Rizzoli, Università di Bologna, Bologna; Rheumatology Unit, Department of Clinical and Experimental Medicine (DIMED), University of Padua, Padua; Rheumatology Unit, Azienda Ospedaliera-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy.
    Objective: The aim of this study was to evaluate the influence of sex on response to treatment and disease remission in patients with axial spondyloarthritis (axSpA).

    Methods: In this retrospective multicenter study, patients with axSpA, according to the Assessment of Spondyloarthritis international Society (ASAS) criteria for axSpA, and treated with adalimumab, etanercept, golimumab, or infliximab, were studied. We compared clinical characteristics, patient-reported outcomes, disease activity, function, and response to treatment in male and female patients with this disease. Read More

    Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.
    Pharmacol Res Perspect 2018 Feb;6(1)
    Pfizer Inc, New York, NY, USA.
    Adverse events are anticipated during a clinical development program. Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We describe here the process undertaken by Pfizer to investigate a safety signal for pancreatic cancer with tofacitinib. Read More

    Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain.
    Rheumatol Int 2018 Feb 7. Epub 2018 Feb 7.
    Servicio de Reumatología, Hospital Universitario Central de Asturias, Oviedo, Spain.
    To define and give priority to standards of care and quality indicators of multidisciplinary care for patients with psoriatic arthritis (PsA). A systematic literature review on PsA standards of care and quality indicators was performed. An expert panel of rheumatologists and dermatologists who provide multidisciplinary care was established. Read More

    Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
    Clin Rheumatol 2018 Feb 7. Epub 2018 Feb 7.
    Department of Emergency and Organ Transplantation-Rheumatology Unit, Policlinico, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy.
    This study aims to evaluate the drug survival and effectiveness of ustekinumab in psoriatic arthritis (PsA) patients naïve to biologics or inadequate responders to tumor necrosis factor (TNF-IR) inhibitors in real life. PsA patients starting ustekinumab were enrolled from 2014 to 2016. Joint involvement, peripheral or axial, Psoriatic Area Severity Index, Disease Activity Psoriatic Arthritis (DAPSA), Lee Enthesitis Index, Health Assessment Questionnaire, body mass index, comorbidities, co-therapies, mechanism of action, and causes of discontinuation of prior TNFi were collected at baseline, and 6 and 12 months. Read More

    Involvement of foot in patients with spondyloarthritis: Prevalence and clinical features.
    Foot Ankle Surg 2017 Nov 10. Epub 2017 Nov 10.
    Department of Rheumatology, Charles Nicolle Hospital, 1006 Tunis, Tunisia; Université de Tunis El Manar, Faculté de Médecine de Tunis, 1007 Tunis, Tunisia.
    Background: The purpose of this study was to evaluate the foot involvement in a group of patients with spondyloarthritis in regard to symptoms, type and frequency of deformities, location and radiological changes.

    Methods: We conducted a cross sectional study including 60 patients with spondyloarthritis over a period of six months. Anamnesis, clinical examination, podoscopic examination, biological tests and X-rays of feet were done for each patient. Read More

    Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study.
    Arthritis Care Res (Hoboken) 2018 Feb 6. Epub 2018 Feb 6.
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States of America.
    Objective: To evaluate minimal disease activity (MDA) among psoriatic arthritis (PsA) patients receiving secukinumab through 2 years in the FUTURE 2 study (NCT01752634).

    Methods: Patients with active PsA were randomized to receive subcutaneous secukinumab 300, 150, or 75 mg or placebo. MDA was assessed in the overall population (anti-tumor necrosis factor [TNF]-naïve and inadequate responders [anti-TNF-IR]) and in patients stratified by prior anti-TNF exposure and by time since diagnosis at Weeks 16, 24, 52, and 104. Read More

    Characterization of Patients With Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the US-Based Corrona Registry.
    Arthritis Care Res (Hoboken) 2018 Feb 6. Epub 2018 Feb 6.
    Corrona, LLC, Southborough, Massachusetts.
    Objective: To describe the characteristics of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) in the United States.

    Methods: Demographics, clinical characteristics, patient-reported outcomes, and treatment characteristics of patients with AS and nr-axSpA were assessed at the time of enrollment in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. AS was defined as patients who fulfilled the 1984 modified New York criteria for AS; nr-axSpA was defined as all other patients with axSpA who did not fulfill the radiologic criterion. Read More

    Comorbidity profiles of psoriasis in Taiwan: A latent class analysis.
    PLoS One 2018 6;13(2):e0192537. Epub 2018 Feb 6.
    Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan.
    Background: Psoriasis is associated with many comorbidities. An understanding of these comorbidity patterns can help foster better care of patients with psoriasis.

    Objective: To identify the heterogeneity of psoriasis comorbidities using latent class analysis (LCA). Read More

    2017 Update of French Society for Rheumatology (SFR) Recommendations about the Everyday Management of Patients with Spondyloarthritis.
    Joint Bone Spine 2018 Jan 30. Epub 2018 Jan 30.
    Paris Descartes University, Department of Rheumatology, Hôpital Cochin, AP-HP, EULAR center of excellence, Paris, France; INSERM (UU1153), Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Paris 14, France.
    Objective: To update French Society for Rheumatology recommendations about the management in clinical practice of patients with spondyloarthritis (SpA). SpA is considered across the range of clinical phenotypes (axial, peripheral, and entheseal) and concomitant manifestations. Psoriatic arthritis is included among the SpA phenotypes. Read More

    Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis.
    Semin Arthritis Rheum 2018 Jan 6. Epub 2018 Jan 6.
    Laboratory of Healthcare Research and Pharmacoepidemiology, Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Via Bicocca degli Arcimboldi 8, 20126 Milan, Italy.
    Background: Psoriatic arthritis (PsA) is a specific form of inflammatory arthritis associated with psoriasis affecting in the same measure men and women but with a consistent geographic variability. Since the burden of PsA frequency has important implications in the definition of the healthcare policies, it is important to measure the frequency of disease in the general population.

    Objective: To quantify the global health burden of PsA summarizing the data provided by the population-based available studies investigating prevalence and incidence of the disease. Read More

    Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.
    Dermatol Ther (Heidelb) 2018 Feb 1. Epub 2018 Feb 1.
    Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
    Introduction: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy in the treatment of moderate to severe plaque psoriasis (PsO) and psoriatic arthritis (PsA), demonstrating a rapid onset of action and sustained responses with a favorable safety profile. All biotherapeutics, including monoclonal antibodies (mAbs), can be immunogenic, leading to formation of anti-drug antibodies (ADAs) that can result in loss of response and adverse events such as hypersensitivity reactions. Thus, the immunogenicity potential of biotherapeutics is of particular interest for physicians. Read More

    Physical activity behaviour in men with inflammatory joint disease: a cross-sectional register-based study.
    Rheumatology (Oxford) 2018 Jan 29. Epub 2018 Jan 29.
    The DANBIO Registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.
    Objectives: Physical activity is recommended as an essential part of the non-pharmacological management of inflammatory joint disease, but previous research in this area has predominantly included women. The aim of this study was to examine physical activity behaviour in men with inflammatory joint disease.

    Methods: The study was conducted as a cross-sectional register-based study. Read More

    Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis.
    PLoS One 2018 1;13(2):e0192010. Epub 2018 Feb 1.
    Focused research unit for Molecular Diagnostic and Clinical Research, IRS-Center Soenderjylland, Hospital of Southern Jutland, Aabenraa, Denmark.
    Background: Psoriasis (PsO) is a chronic inflammatory disease with predominantly cutaneous manifestations. Approximately one third of patients with PsO develop psoriatic arthritis (PsA), whereas the remaining proportion of patients has isolated cutaneous psoriasis (PsC). These two phenotypes share common immunology, but with different heredity that might in part be explained by genetic variables. Read More

    Real world data on the efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis.
    J Eur Acad Dermatol Venereol 2018 Feb 1. Epub 2018 Feb 1.
    A Sygros Hospital, 5 Ionos Dragoumi str, Rimini 1, Chaidari12462, Athens, Greece.
    Background: Psoriasis is a chronic inflammatory skin disease, which requires long term, safe and effective treatment. Apremilast, a small-molecule PDE4 inhibitor, has been introduced as psoriasis (and psoriatic arthritis) treatment in Europe in 2015.

    Objective: We analysed and report the efficacy and safety of apremilast in the first 51 patients with psoriasis that have undergone treatment with this novel small molecule in our outpatient clinic. Read More

    Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management.
    Psoriasis (Auckl) 2017 15;7:35-40. Epub 2017 Apr 15.
    Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
    The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis factor (TNF)-α agents is a clinical practice issue to face with, particularly if the treatment has a long-term maintenance finality. The aims of this review are to examine the current knowledge on HBVr incidence in chronic HBV carriers and potential occult carriers undergoing therapy with biologics for the treatment of psoriasis and psoriatic arthritis; analyze the prophylactic measure to prevent HBV reactivation and define how to manage HBVr in patients treated with biologics. We searched through PubMed, Google Scholar and Scopus databases and evaluated all published manuscripts concerning HBVr in psoriatic patients, both plaque-type and psoriatic arthritis, in treatment with any indicated anti-TNF-α. Read More

    Local effects of adipose tissue in psoriasis and psoriatic arthritis.
    Psoriasis (Auckl) 2017 3;7:17-25. Epub 2017 Feb 3.
    Department of Dermatology and Allergology, Hospital Dresden-Friedrichstadt Academic Teaching Hospital of the Technical University of Dresden, Dresden, Germany.
    The structure and physiological state of the local white adipose tissue (WAT) located underneath the lesional psoriatic skin and inside of the joints affected by psoriatic arthritis play an important role in the pathophysiology of these diseases. WAT pads associated with inflammatory sites in psoriasis and psoriatic arthritis are, correspondingly, dermal WAT and articular adipose tissue; these pads demonstrate inflammatory phenotypes in both diseases. Such local WAT inflammation could be the primary effect in the pathophysiology of psoriasis leading to the modification of the local expression of adipokines, a change in the structure of the basement membrane and the release of keratinocytes with consequent epidermal hyperproliferation during psoriasis. Read More

    Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis.
    Ther Clin Risk Manag 2018 9;14:105-116. Epub 2018 Jan 9.
    Department of Emergency and Organ Transplantation, Rheumatology Unit, University of Bari, Bari, Italy.
    Methotrexate (MTX) is one of the mainstays of treatment for several immune-mediated inflammatory joint and skin diseases, especially rheumatoid arthritis (RA) and moderate-to-severe psoriasis. Oral MTX has been used for the treatment of such diseases for decades for many reasons. There is, however, a relevant interpatient variability of clinical and safety outcomes that can also be related to differences in patients' individual pharmacogenomic profile. Read More

    Experiences of a patient-initiated self-monitoring service in inflammatory arthritis: A qualitative exploration.
    Musculoskeletal Care 2018 Jan 30. Epub 2018 Jan 30.
    Centre for Rheumatology, University College London Hospital, London, UK.
    Objectives: The aim of the present study was to explore patients' experience of a patient-initiated self-monitoring service for people with rheumatoid or psoriatic arthritis who are on methotrexate.

    Methods: The study took the form of qualitative semi-structured interviews, embedded within a randomized controlled trial. Twelve participants who were randomly assigned to the intervention arm were interviewed. Read More

    Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?
    Clin Rheumatol 2018 Jan 29. Epub 2018 Jan 29.
    Rheumatology Division, Arthritis Unit, Hospital Clinic, Barcelona, Spain.
    Cardiovascular risk factors (CVRFs) have been related to poorer responses to systemic therapy in psoriatic arthritis (PsA). We aimed to evaluate the potential association between CVRFs and the achievement of therapeutic goals in PsA patients receiving systemic therapy. A cross-sectional study was carried out at 25 rheumatology outpatient clinics in Spain. Read More

    Interaction between microbiome and host genetics in psoriatic arthritis.
    Autoimmun Rev 2018 Feb 1. Epub 2018 Feb 1.
    Rheumatology, Allergology and Clinical Immunology, Department of Medicina dei Sistemi, University of Rome Tor Vergata, Rome, Italy.
    Psoriatic arthritis (PsA) is a chronic inflammatory joint disease, seen in combination with psoriasis. Both genetic and environmental factors are responsible for the development of PsA, however little is known about the different weight of these two distinctive components in the pathogenesis of the disease. Genomic variability in PsA is associated with the disease and/or some peculiar clinical phenotypes. Read More

    Incidence of diseases primarily affecting the skin by age group: population-based epidemiologic study in Olmsted County, Minnesota, and comparison with age-specific incidence rates worldwide.
    Int J Dermatol 2018 Jan 29. Epub 2018 Jan 29.
    Division of Clinical Dermatology, Mayo Clinic, Rochester, MN, USA.
    Understanding the effects of age on the epidemiology of diseases primarily affecting the skin is important to the practice of dermatology, both for proper allocation of resources and for optimal patient-centered care. To fully appreciate the effect that age may have on the population-based calculations of incidence of diseases primarily affecting the skin in Olmsted County, Minnesota, and worldwide, we performed a review of all relevant Rochester Epidemiology Project-published data and compared them to similar reports in the worldwide English literature. Using the Rochester Epidemiology Project, population-based epidemiologic studies have been performed to estimate the incidence of specific skin diseases over the past 50 years. Read More

    Increased Frequency of Peripheral B and T Cells Expressing Granulocyte Monocyte Colony-Stimulating Factor in Rheumatoid Arthritis Patients.
    Front Immunol 2017 10;8:1967. Epub 2018 Jan 10.
    Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece.
    Objectives: Granulocyte monocyte colony-stimulating factor (GM-CSF) is currently considered a crucial inflammatory mediator and a novel therapeutic target in rheumatoid arthritis (RA), despite the fact that its precise cellular sources remain uncertain. We studied the expression of GM-CSF in peripheral lymphocytes from RA patients and its change with antirheumatic therapies.

    Methods: Intracellular GM-CSF expression was assessed by flow cytometry in stimulated peripheral B (CD19+) and T (CD3+) cells from RA patients ( = 40), disease ( = 31 including osteoarthritis = 15, psoriatic arthritis = 10, and systemic rheumatic diseases = 6) and healthy ( = 16) controls. Read More

    Clustered multistate models with observation level random effects, mover-stayer effects and dynamic covariates: modelling transition intensities and sojourn times in a study of psoriatic arthritis.
    J R Stat Soc Ser C Appl Stat 2018 Feb 25;67(2):481-500. Epub 2017 Jul 25.
    University of Cambridge, UK.
    In psoriatic arthritis, it is important to understand the joint activity (represented by swelling and pain) and damage processes because both are related to severe physical disability. The paper aims to provide a comprehensive investigation into both processes occurring over time, in particular their relationship, by specifying a joint multistate model at the individual hand joint level, which also accounts for many of their important features. As there are multiple hand joints, such an analysis will be based on the use of clustered multistate models. Read More

    1 OF 174